Action PharmAla Biotech (QB) - MDXXF

PharmAla Biotech Holdings Inc (QB) (MDXXF) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,0997

( - )

Prix Achat

0,02

Prix Vente

0,1317

Volume échangé

0,00 Fourchette du Jour 0,00

0,0614 Plage de 52 semaines 0,1511

Cap du marché

10,856M

Clôture Veille

0,0997

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

US$ 208 397

Actions en circulation

108 887 215

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-9,03

Bénéfice par action (BPA)

-0,02

Chiffre d'affairess (LTM)

889,57k

Bénéfice net (LTM)

-1,63M

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headqu... Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

pharmala.ca

Siège social

Vancouver, Canada

Fondé

PharmAla Biotech Holdings Inc (QB) est coté dans le secteur Healthcare de la OTC Markets avec le ticker MDXXF. Le dernier cours de clôture d'PharmAla Biotech (QB) était de US$0,10. Au cours de la dernière année, les actions de PharmAla Biotech (QB) ont été négociées dans une fourchette de prix de US$ 0,0614 à US$ 0,1511.

PharmAla Biotech (QB) compte actuellement 108 887 215 actions en circulation. La capitalisation boursière d'PharmAla Biotech (QB) est de US$10,86 million. PharmAla Biotech (QB) a un ratio cours/bénéfice (ratio PE) de -9.03.

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a...

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing...

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President...

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF...

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”...

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading...

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.0003	-0.3	0.1	0.107975	0.0997	4567	0.10047263	CS
4	-0.0086	-7.94090489381	0.1083	0.1198	0.0889	30107	0.10913896	CS
12	0.025	33.4672021419	0.0747	0.1511	0.064	63538	0.11602584	CS
26	0.01765	21.5112736137	0.08205	0.1511	0.064	44802	0.11299462	CS
52	0.02039	25.7092422141	0.07931	0.1511	0.0614	36373	0.09881391	CS
156	-0.0503	-33.5333333333	0.15	0.35	0.04005	32904	0.12677405	CS
260	-0.0503	-33.5333333333	0.15	0.35	0.04005	32904	0.12677405	CS

MDXXF - Frequently Asked Questions (FAQ)

What is the current PharmAla Biotech Holdings Inc (QB) share price?

The current share price of PharmAla Biotech Holdings Inc (QB) is US$ 0,0997

How many PharmAla Biotech Holdings Inc (QB) shares are in issue?

PharmAla Biotech Holdings Inc (QB) has 108 887 215 shares in issue

What is the market cap of PharmAla Biotech Holdings Inc (QB)?

The market capitalisation of PharmAla Biotech Holdings Inc (QB) is USD 10,86M

What is the 1 year trading range for PharmAla Biotech Holdings Inc (QB) share price?

PharmAla Biotech Holdings Inc (QB) has traded in the range of US$ 0,0614 to US$ 0,1511 during the past year

What is the PE ratio of PharmAla Biotech Holdings Inc (QB)?

The price to earnings ratio of PharmAla Biotech Holdings Inc (QB) is -9,03

What is the cash to sales ratio of PharmAla Biotech Holdings Inc (QB)?

The cash to sales ratio of PharmAla Biotech Holdings Inc (QB) is 17,14

What is the registered address of PharmAla Biotech Holdings Inc (QB)?

The registered address for PharmAla Biotech Holdings Inc (QB) is 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7

What is the PharmAla Biotech Holdings Inc (QB) website address?

The website address for PharmAla Biotech Holdings Inc (QB) is pharmala.ca

Which industry sector does PharmAla Biotech Holdings Inc (QB) operate in?

PharmAla Biotech Holdings Inc (QB) operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PharmAla Biotech Holdings Inc (QB) (MDXXF)

PharmAla Biotech Holdings Inc (QB) (MDXXF) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de PharmAla Biotech Holdings Inc (QB)

MDXXF Dernières nouvelles

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

MDXXF - Frequently Asked Questions (FAQ)

MDXXF Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités